Do analysts prefer IZTC or IMRN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Invizyne Technologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Immuron 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation & earnings, IZTC or IMRN?

Invizyne Technologies has higher earnings, but lower revenue than Immuron. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Invizyne Technologies N/A N/A N/A N/A N/A Immuron $4.72M 1.95 -$3.38M N/A N/A

Is IZTC or IMRN more profitable?

Company Net Margins Return on Equity Return on Assets Invizyne Technologies N/A N/A N/A Immuron N/A N/A N/A

Do analysts prefer MDXH or IMRN?

MDxHealth currently has a consensus price target of $2.17, indicating a potential upside of 174.68%. Given MDxHealth's stronger consensus rating and higher possible upside, research analysts clearly believe MDxHealth is more favorable than Immuron. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MDxHealth 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40 Immuron 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings & valuation, MDXH or IMRN?

Immuron has lower revenue, but higher earnings than MDxHealth. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MDxHealth $107.88M 0.36 -$33.52M -$0.72 N/A Immuron $4.72M 1.95 -$3.38M N/A N/A

Is MDXH or IMRN more profitable?

Immuron has a net margin of 0.00% compared to MDxHealth's net margin of -33.46%. Company Net Margins Return on Equity Return on Assets MDxHealth -33.46% N/A -24.25% Immuron N/A N/A N/A

Does the media favor MDXH or IMRN?

In the previous week, MDxHealth had 3 more articles in the media than Immuron. MarketBeat recorded 5 mentions for MDxHealth and 2 mentions for Immuron. Immuron's average media sentiment score of 0.22 beat MDxHealth's score of -0.20 indicating that Immuron is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MDxHealth 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Immuron 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend IMRN or GOSS?

Gossamer Bio has a consensus price target of $3.20, indicating a potential upside of 1,464.79%. Given Gossamer Bio's stronger consensus rating and higher probable upside, analysts clearly believe Gossamer Bio is more favorable than Immuron. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Immuron 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Gossamer Bio 2 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.22

Which has preferable earnings & valuation, IMRN or GOSS?

Immuron has higher earnings, but lower revenue than Gossamer Bio. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immuron $4.72M 1.95 -$3.38M N/A N/A Gossamer Bio $48.47M 0.99 -$170.37M -$0.70 N/A

Is IMRN or GOSS more profitable?

Immuron has a net margin of 0.00% compared to Gossamer Bio's net margin of -235.00%. Company Net Margins Return on Equity Return on Assets Immuron N/A N/A N/A Gossamer Bio -235.00% N/A -112.04%

Does the media refer more to IMRN or GOSS?

In the previous week, Gossamer Bio had 3 more articles in the media than Immuron. MarketBeat recorded 5 mentions for Gossamer Bio and 2 mentions for Immuron. Gossamer Bio's average media sentiment score of 0.42 beat Immuron's score of 0.22 indicating that Gossamer Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immuron 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Gossamer Bio 0 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend RADX or IMRN?

Radiopharm Theranostics currently has a consensus price target of $11.00, indicating a potential upside of 343.55%. Given Radiopharm Theranostics' stronger consensus rating and higher probable upside, analysts plainly believe Radiopharm Theranostics is more favorable than Immuron. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Radiopharm Theranostics 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Immuron 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings & valuation, RADX or IMRN?

Immuron has higher revenue and earnings than Radiopharm Theranostics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Radiopharm Theranostics $2.35M 15.26 -$24.83M N/A N/A Immuron $4.72M 1.95 -$3.38M N/A N/A

Is RADX or IMRN more profitable?

Company Net Margins Return on Equity Return on Assets Radiopharm Theranostics N/A N/A N/A Immuron N/A N/A N/A

Does the media favor RADX or IMRN?

In the previous week, Radiopharm Theranostics had 2 more articles in the media than Immuron. MarketBeat recorded 4 mentions for Radiopharm Theranostics and 2 mentions for Immuron. Immuron's average media sentiment score of 0.22 beat Radiopharm Theranostics' score of 0.00 indicating that Immuron is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Radiopharm Theranostics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Immuron 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate IMRN or ATNM?

Actinium Pharmaceuticals has a consensus target price of $5.00, suggesting a potential upside of 362.96%. Given Actinium Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Actinium Pharmaceuticals is more favorable than Immuron. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Immuron 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Actinium Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00

Which has preferable valuation & earnings, IMRN or ATNM?

Immuron has higher earnings, but lower revenue than Actinium Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immuron $4.72M 1.95 -$3.38M N/A N/A Actinium Pharmaceuticals $35.09M 0.97 -$48.82M $0.36 3.00

Is IMRN or ATNM more profitable?

Immuron's return on equity of 0.00% beat Actinium Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Immuron N/A N/A N/A Actinium Pharmaceuticals N/A -100.85% -47.89%

Immuron (IMRN) Competitors

$1.14 +0.02 (+1.79%)

Closing price 08/25/2026 03:59 PM Eastern

Extended Trading

$1.14 +0.01 (+0.44%)

As of 08/25/2026 04:10 PM Eastern

Compare

IMRN vs. IZTC, MDXH, GOSS, RADX, and ATNM

Should you buy Immuron stock or one of its competitors? Immuron's main competitors and comparable companies include Invizyne Technologies (IZTC), MDxHealth (MDXH), Gossamer Bio (GOSS), Radiopharm Theranostics (RADX), and Actinium Pharmaceuticals (ATNM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Immuron compare to Invizyne Technologies?

Invizyne Technologies (NASDAQ:IZTC) and Immuron (NASDAQ:IMRN) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, media sentiment, risk, valuation, institutional ownership, earnings, analyst recommendations and profitability.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Invizyne Technologies	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Immuron	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Invizyne Technologies has higher earnings, but lower revenue than Immuron.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Invizyne Technologies	N/A	N/A	N/A	N/A	N/A
Immuron	$4.72M	1.95	-$3.38M	N/A	N/A

Company	Net Margins	Return on Equity	Return on Assets
Invizyne Technologies	N/A	N/A	N/A
Immuron	N/A	N/A	N/A

0.1% of Immuron shares are held by institutional investors. 7.0% of Immuron shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Immuron had 2 more articles in the media than Invizyne Technologies. MarketBeat recorded 2 mentions for Immuron and 0 mentions for Invizyne Technologies. Immuron's average media sentiment score of 0.22 beat Invizyne Technologies' score of 0.00 indicating that Immuron is being referred to more favorably in the news media.

Company	Overall Sentiment
Invizyne Technologies	Neutral
Immuron	Neutral

Summary

Immuron beats Invizyne Technologies on 6 of the 6 factors compared between the two stocks.

How does Immuron compare to MDxHealth?

MDxHealth (NASDAQ:MDXH) and Immuron (NASDAQ:IMRN) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, risk, analyst recommendations, profitability, media sentiment, dividends, earnings and valuation.

In the previous week, MDxHealth had 3 more articles in the media than Immuron. MarketBeat recorded 5 mentions for MDxHealth and 2 mentions for Immuron. Immuron's average media sentiment score of 0.22 beat MDxHealth's score of -0.20 indicating that Immuron is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MDxHealth	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Immuron	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

MDxHealth has a beta of 1.42, meaning that its share price is 42% more volatile than the broader market. Comparatively, Immuron has a beta of 1.15, meaning that its share price is 15% more volatile than the broader market.

Immuron has a net margin of 0.00% compared to MDxHealth's net margin of -33.46%.

Company	Net Margins	Return on Equity	Return on Assets
MDxHealth	-33.46%	N/A	-24.25%
Immuron	N/A	N/A	N/A

Immuron has lower revenue, but higher earnings than MDxHealth.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MDxHealth	$107.88M	0.36	-$33.52M	-$0.72	N/A
Immuron	$4.72M	1.95	-$3.38M	N/A	N/A

0.1% of Immuron shares are owned by institutional investors. 1.7% of MDxHealth shares are owned by insiders. Comparatively, 7.0% of Immuron shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

MDxHealth currently has a consensus price target of $2.17, indicating a potential upside of 174.68%. Given MDxHealth's stronger consensus rating and higher possible upside, research analysts clearly believe MDxHealth is more favorable than Immuron.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MDxHealth	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Immuron	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Immuron beats MDxHealth on 7 of the 13 factors compared between the two stocks.

How does Immuron compare to Gossamer Bio?

Immuron (NASDAQ:IMRN) and Gossamer Bio (NASDAQ:GOSS) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, analyst recommendations, media sentiment, risk, dividends, profitability and institutional ownership.

Gossamer Bio has a consensus price target of $3.20, indicating a potential upside of 1,464.79%. Given Gossamer Bio's stronger consensus rating and higher probable upside, analysts clearly believe Gossamer Bio is more favorable than Immuron.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immuron	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Gossamer Bio	2 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.22

Immuron has a net margin of 0.00% compared to Gossamer Bio's net margin of -235.00%.

Company	Net Margins	Return on Equity	Return on Assets
Immuron	N/A	N/A	N/A
Gossamer Bio	-235.00%	N/A	-112.04%

In the previous week, Gossamer Bio had 3 more articles in the media than Immuron. MarketBeat recorded 5 mentions for Gossamer Bio and 2 mentions for Immuron. Gossamer Bio's average media sentiment score of 0.42 beat Immuron's score of 0.22 indicating that Gossamer Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immuron	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Gossamer Bio	0 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Immuron has higher earnings, but lower revenue than Gossamer Bio.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immuron	$4.72M	1.95	-$3.38M	N/A	N/A
Gossamer Bio	$48.47M	0.99	-$170.37M	-$0.70	N/A

Immuron has a beta of 1.15, suggesting that its share price is 15% more volatile than the broader market. Comparatively, Gossamer Bio has a beta of 2.04, suggesting that its share price is 104% more volatile than the broader market.

0.1% of Immuron shares are held by institutional investors. Comparatively, 81.2% of Gossamer Bio shares are held by institutional investors. 7.0% of Immuron shares are held by insiders. Comparatively, 3.7% of Gossamer Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Gossamer Bio beats Immuron on 8 of the 13 factors compared between the two stocks.

How does Immuron compare to Radiopharm Theranostics?

Radiopharm Theranostics (NASDAQ:RADX) and Immuron (NASDAQ:IMRN) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, profitability, risk and valuation.

Radiopharm Theranostics has a beta of 1.63, indicating that its stock price is 63% more volatile than the broader market. Comparatively, Immuron has a beta of 1.15, indicating that its stock price is 15% more volatile than the broader market.

Immuron has higher revenue and earnings than Radiopharm Theranostics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Radiopharm Theranostics	$2.35M	15.26	-$24.83M	N/A	N/A
Immuron	$4.72M	1.95	-$3.38M	N/A	N/A

Company	Net Margins	Return on Equity	Return on Assets
Radiopharm Theranostics	N/A	N/A	N/A
Immuron	N/A	N/A	N/A

In the previous week, Radiopharm Theranostics had 2 more articles in the media than Immuron. MarketBeat recorded 4 mentions for Radiopharm Theranostics and 2 mentions for Immuron. Immuron's average media sentiment score of 0.22 beat Radiopharm Theranostics' score of 0.00 indicating that Immuron is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Radiopharm Theranostics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Immuron	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

0.1% of Immuron shares are owned by institutional investors. 7.0% of Immuron shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Radiopharm Theranostics currently has a consensus price target of $11.00, indicating a potential upside of 343.55%. Given Radiopharm Theranostics' stronger consensus rating and higher probable upside, analysts plainly believe Radiopharm Theranostics is more favorable than Immuron.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Radiopharm Theranostics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Immuron	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Radiopharm Theranostics beats Immuron on 6 of the 11 factors compared between the two stocks.

How does Immuron compare to Actinium Pharmaceuticals?

Immuron (NASDAQ:IMRN) and Actinium Pharmaceuticals (NYSE:ATNM) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, profitability, institutional ownership, risk, analyst recommendations, earnings and media sentiment.

In the previous week, Immuron had 2 more articles in the media than Actinium Pharmaceuticals. MarketBeat recorded 2 mentions for Immuron and 0 mentions for Actinium Pharmaceuticals. Immuron's average media sentiment score of 0.22 beat Actinium Pharmaceuticals' score of 0.00 indicating that Immuron is being referred to more favorably in the media.

Company	Overall Sentiment
Immuron	Neutral
Actinium Pharmaceuticals	Neutral

Immuron has a beta of 1.15, meaning that its stock price is 15% more volatile than the broader market. Comparatively, Actinium Pharmaceuticals has a beta of 0.01, meaning that its stock price is 99% less volatile than the broader market.

Actinium Pharmaceuticals has a consensus target price of $5.00, suggesting a potential upside of 362.96%. Given Actinium Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Actinium Pharmaceuticals is more favorable than Immuron.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immuron	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Actinium Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Immuron has higher earnings, but lower revenue than Actinium Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immuron	$4.72M	1.95	-$3.38M	N/A	N/A
Actinium Pharmaceuticals	$35.09M	0.97	-$48.82M	$0.36	3.00

0.1% of Immuron shares are owned by institutional investors. Comparatively, 27.5% of Actinium Pharmaceuticals shares are owned by institutional investors. 7.0% of Immuron shares are owned by company insiders. Comparatively, 0.6% of Actinium Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Immuron's return on equity of 0.00% beat Actinium Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immuron	N/A	N/A	N/A
Actinium Pharmaceuticals	N/A	-100.85%	-47.89%

Summary

Immuron beats Actinium Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

Get Immuron News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMRN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IMRN vs. The Competition

Export

Metric	Immuron	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$9.04M	$4.00B	$7.35B	$12.72B
Dividend Yield	N/A	3.63%	2.53%	11.02%
P/E Ratio	N/A	11.81	270.96	24.14
Price / Sales	1.95	1,410.01	642.82	101.63
Price / Cash	N/A	103.64	78.57	53.12
Price / Book	1.46	16.87	13.14	6.25
Net Income	-$3.38M	-$22.76M	$3.46B	$347.86M
7 Day Performance	-4.20%	1.81%	1.51%	0.98%
1 Month Performance	2.70%	12.24%	8.80%	5.24%
1 Year Performance	-35.23%	57.38%	26.08%	17.04%

Immuron Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IMRN Immuron	0.4237 of 5 stars	$1.14 +1.8%	N/A	-36.8%	$9.04M	$4.72M	N/A	N/A	Upcoming Earnings Gap Up
IZTC Invizyne Technologies	N/A	$6.03 +3.6%	N/A	-25.3%	$37.70M	N/A	N/A	29	Gap Down
MDXH MDxHealth	2.4765 of 5 stars	$0.76 +1.2%	$2.83 +272.8%	-77.7%	$37.62M	$107.88M	N/A	300
GOSS Gossamer Bio	2.7349 of 5 stars	$0.16 +9.4%	$3.20 +1,943.4%	-91.3%	$36.75M	$48.47M	N/A	180	Gap Up
RADX Radiopharm Theranostics	3.461 of 5 stars	$2.50 -4.6%	$11.00 +340.0%	-55.7%	$36.15M	$2.35M	N/A	N/A	Short Interest Decrease

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IMRN) was last updated on 8/26/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Immuron (IMRN) Competitors

IMRN vs. IZTC, MDXH, GOSS, RADX, and ATNM

How does Immuron compare to Invizyne Technologies?

Summary

How does Immuron compare to MDxHealth?

Summary

How does Immuron compare to Gossamer Bio?

Summary

How does Immuron compare to Radiopharm Theranostics?

Summary

How does Immuron compare to Actinium Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMRN vs. The Competition

Immuron Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Immuron (IMRN) Competitors

IMRN vs. IZTC, MDXH, GOSS, RADX, and ATNM

How does Immuron compare to Invizyne Technologies?

Do analysts prefer IZTC or IMRN?

Which has preferable valuation & earnings, IZTC or IMRN?

Is IZTC or IMRN more profitable?

Do institutionals and insiders hold more shares of IZTC or IMRN?

Does the media refer more to IZTC or IMRN?

Summary

How does Immuron compare to MDxHealth?

Does the media favor MDXH or IMRN?

Which has more volatility and risk, MDXH or IMRN?

Is MDXH or IMRN more profitable?

Which has better earnings & valuation, MDXH or IMRN?

Do institutionals & insiders believe in MDXH or IMRN?

Do analysts prefer MDXH or IMRN?

Summary

How does Immuron compare to Gossamer Bio?

Do analysts recommend IMRN or GOSS?

Is IMRN or GOSS more profitable?

Does the media refer more to IMRN or GOSS?

Which has preferable earnings & valuation, IMRN or GOSS?

Which has more risk and volatility, IMRN or GOSS?

Do institutionals and insiders have more ownership in IMRN or GOSS?

Summary

How does Immuron compare to Radiopharm Theranostics?

Which has more risk & volatility, RADX or IMRN?

Which has higher earnings & valuation, RADX or IMRN?

Is RADX or IMRN more profitable?

Does the media favor RADX or IMRN?

Do insiders and institutionals believe in RADX or IMRN?

Do analysts recommend RADX or IMRN?

Summary

How does Immuron compare to Actinium Pharmaceuticals?

Does the media refer more to IMRN or ATNM?

Which has more risk and volatility, IMRN or ATNM?

Do analysts rate IMRN or ATNM?

Which has preferable valuation & earnings, IMRN or ATNM?

Do insiders & institutionals hold more shares of IMRN or ATNM?

Is IMRN or ATNM more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMRN vs. The Competition

Immuron Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools